A series of 1,7-diphenyl-1,4-heptadien-3-ones with various substituents (HO-, CH3O-, CH3-, Cl-) on the phenyl rings were synthesized and evaluated for anti-neuroinflammatory effects in LPS-stimulated BV2 microglia. The pharmacological results showed that the target compounds bearing methoxy groups greatly inhibited LPS-induced NO release, and that the active compounds CU-19 and CU-21 reduced the level of NO, TNF-α, IL-6 and PGE-2, downregulated the expression of COX-2 and iNOS in LPS-stimulated BV2 cells. A study of the mechanism of action revealed that CU-19 and CU-21 inhibited the nuclear translocation of NF-κB and phosphorylation of MAPKs (ERK, JNK, and p38). A preliminary pharmacokinetic study in rats revealed that the pharmacokinetic properties of CU-19 and CU-21 were dramatically ameliorated in comparison with the pharmacokinetic properties of curcumin.
一系列具有不同取代基(HO-,CH3O-,CH3-,Cl-)的1,7-二苯基-1,4-庚二烯-3-酮被合成并在LPS刺激的BV2小胶质细胞中评估其抗神经炎症作用。药理结果显示,带有甲氧基的目标化合物极大地抑制了LPS诱导的NO释放,并且活性化合物CU-19和CU-21降低了LPS刺激的BV2细胞中NO,TNF-α,IL-6和PGE-2的水平,下调了COX-2和iNOS的表达。机制研究表明,CU-19和CU-21抑制了NF-κB的核转运和MAPKs(ERK,JNK和p38)的磷酸化。大鼠的初步药代动力学研究表明,与姜黄素的药代动力学性质相比,CU-19和CU-21的药代动力学性质显著改善。